Search results for "Neoplastic"

showing 10 items of 2901 documents

Human Papilloma Virus-Dependent HMGA1 Expression Is a Relevant Step in Cervical Carcinogenesis

2008

HMGA1 is a member of a small family of architectural transcription factors involved in the coordinate assembly of multiprotein complexes referred to as enhanceosomes. In addition to their role in cell proliferation, differentiation, and development, high-mobility group proteins of the A type (HMGA) family members behave as transforming protoncogenes either in vitro or in animal models. Recent reports indicated that HMGA1 might counteract p53 pathway and provided an interesting hint on the mechanisms determining HMGA's transforming potential. HMGA1 expression is deregulated in a very large array of human tumors, including cervical cancer, but very limited information is available on the mole…

Uterine Cervical NeoplasmCancer ResearchDNA-Binding ProteinBiologyHeLa Celllcsh:RC254-282DNA-binding proteinRNA interferenceCell Line TumorHMGA1a ProteinRNA MessengerReceptor Notch1PapillomaviridaePapillomavirus InfectionPsychological repressionTranscription factorCell ProliferationReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingHMGAOncogene Proteins ViralCell Transformation Virallcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHMGA1Gene Expression Regulation NeoplasticGene expression profilingCancer cellCancer researchbiology.proteinFemaleTumor Suppressor Protein p53HumanNeoplasia
researchProduct

Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer

2012

Objective: The aim of this study is to assess our results of treatment of women with stage I cervical cancer > 2 cm in diameter seeking fertility preservation. Treatment consisted of Laparoscopic Pelvic and Paraaortic Lymphadenectomy (LPPLND), and when no nodal metastasis was detected, neoadjuvant chemotherapy (NACT) followed by radical vaginal trachelectomy (RVT). Patients with positive lymph nodes underwent primary chemoradiation. Methods: A cohort of women younger than 40 years of age with stage I disease > 2 cm who underwent LPPLND and either NACT and RVT or chemoradiation. Oncological outcome was evaluated prospectively. Results: Eighteen women were eligible for this study. Twelve (67%…

Uterine Cervical NeoplasmRVTmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCervix UteriMetastasisParaaortic lymph nodesAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesFertility preservationProspective cohort studyLymph nodeNeoadjuvant therapyCervical cancerFertility PreservationObstetrics and GynecologyChemoradiotherapyNeoadjuvant Therapymedicine.anatomical_structureOncologyChemotherapy AdjuvantLymphatic MetastasisCarcinoma Squamous CellFemaleRadiologyHumanAdultmedicine.medical_specialtyPaclitaxelPelviRadical vaginal trachelectomyCervical carcinoma; Radical vaginal trachelectomy; Neoadjuvant chemotherapyAdenocarcinomaNeoadjuvant chemotherapyPelvisFollow-Up StudieHumansIfosfamideCervical carcinomaNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryGeneral surgeryLymphatic Metastasimedicine.diseaseProspective StudieLymph Node ExcisionLaparoscopyCisplatinNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective…

2015

Objective The International Federation of Gynecology and Obstetrics (FIGO) staging for cervical cancer is based on clinical examination. Previous studies have demonstrated significant upstaging with surgical staging. However, no randomized trial has ever shown a survival benefit when radiation combined with chemoradiation (RCTX) is modified according to surgical staging. The objective of the study was to evaluate the feasibility and outcomes of surgical staging prior to radical RCTX treatment among patients with locally advanced cervical cancer in the setting of a larger, prospective, randomized study (the Uterus-11 study of the German Gynecologic Oncology Group). Study Design Between 2009 …

Uterine Cervical Neoplasmmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCarcinoma AdenosquamouAntineoplastic AgentPostoperative ComplicationsLaparotomyrandomized triallocally advanced cervical cancerLaparoscopyCervical cancermedicine.diagnostic_testMedicine (all)Lymph NodeObstetrics and GynecologyChemoradiotherapyMiddle Agedlaparoscopic stagingTreatment OutcomeCarcinoma Squamous CellFemaleoperative morbidityHumanAdultmedicine.medical_specialtyPelviBrachytherapyAntineoplastic AgentsGynecologic oncologyAdenocarcinomaPelvisCarcinoma AdenosquamousYoung AdultmedicineHumansExternal beam radiotherapyAgedNeoplasm StagingRadiotherapybusiness.industryPostoperative complicationPerioperativemedicine.diseaseSurgeryFeasibility StudieFeasibility StudiesLymph Node ExcisionLaparoscopyPostoperative ComplicationLymph NodesCisplatinbusinessAmerican journal of obstetrics and gynecology
researchProduct

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

2008

Uveal melanoma is associated with a high mortality rate once metastases occur, with over >90% of metastatic patients dying within less than 1 year from metastases to the liver. The intraarterial hepatic (iah) administration of the alkylating agent fotemustine holds some promise with response rates of 36% and median survival of 15 months. Here, we investigated whether the DNA-repair-protein MGMT may be involved in the variability of response to fotemustine and temozolomide in uveal melanoma. Epigenetic inactivation of MGMT has been demonstrated to be a predictive marker for benefit from alkylating agent therapy in glioblastoma. We found a methylated MGMT promoter in 6% of liver metastases fr…

Uveal NeoplasmsCancer ResearchPathologymedicine.medical_specialtyProtein Array AnalysisAntineoplastic AgentsBiologyMetastasischemistry.chemical_compoundPredictive Value of TestsmedicineBiomarkers TumorHumansPromoter Regions GeneticneoplasmsDNA Modification MethylasesMelanomaTemozolomidePredictive markerTissue microarrayMelanomaTumor Suppressor ProteinsLiver NeoplasmsCancerDNA Methylationmedicine.diseaseImmunohistochemistrydigestive system diseasesNitrogen mustardDNA Repair EnzymesOncologychemistryCancer researchFotemustinemedicine.drugInternational journal of cancer
researchProduct

Exploring the anticancer potential of pyrazolo[1,2-a]benzo[1,2,3,4] tetrazin-3-one derivatives: The effect on apoptosis induction, cell cycle and pro…

2013

In order to investigate their anticancer potential, four new pyrazolo[1,2-a]benzo[1,2,3,4]-tetrazinone derivatives, designed through the chemometric protocol VLAK, and three of the most active compounds of the previous series have been evaluated on some cellular events including proliferation, apoptosis induction, and cell cycle. The NCI one dose (10 mu M) screening revealed that the 8,9-di-methyl derivative showed activity against Leukemia (CCRF-CEM) and Colon cancer cell line (COLO 205), reaching 81% and 45% of growth inhibition (GI), respectively. Replacement of the two methyl groups with two chlorine atoms maintained the activity toward Leukemia cell (CCRF-CEM, GI 77%) and selectively e…

VLAK protocolStereochemistryCell Survival3Cell2Pyrazolo[1Antineoplastic AgentsApoptosisCell cycleHeLachemistry.chemical_compoundStructure-Activity RelationshipPyrazolo[12-a]benzo[1234]tetrazinone VLAK protocol Anticancer agents Apoptosis inducers Cell cycleCell Line TumorDrug DiscoverymedicineHumans2-a]benzo[1EC50Cell ProliferationPharmacologybiologyDose-Response Relationship DrugMolecular StructureCell growthOrganic ChemistryApoptosis inducers4]tetrazinoneGeneral MedicineCell cyclebiology.organism_classificationmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaLeukemiamedicine.anatomical_structurechemistryApoptosisAnticancer agentsCancer researchGrowth inhibitionHeterocyclic Compounds 3-RingHeLa Cells
researchProduct

Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response

2021

During tumor growth, angiogenesis is required to ensure oxygen and nutrient transport to the tumor. Vascular endothelial growth factor (VEGF) is the major inducer of angiogenesis and appears to be a key modulator of the anti-tumor immune response. Indeed, VEGF modulates innate and adaptive immune responses through direct interactions and indirectly by modulating protein expressions on endothelial cells or vascular permeability. The inhibition of the VEGF signaling pathway is clinically approved for the treatment of several cancers. Therapies targeting VEGF can modulate the tumor vasculature and the immune response. In this review, we discuss the roles of VEGF in the anti-tumor immune respon…

Vascular Endothelial Growth Factor AAngiogenesisAngiogenesis InhibitorsVascular permeabilityReviewAdaptive Immunityimmune responsechemistry.chemical_compoundangiogenesisNeoplasmsVEGF Signaling PathwayInducerBiology (General)SpectroscopyNeovascularization Pathologicvascular endothelial growth factorGeneral MedicineSorafenibComputer Science ApplicationsBevacizumabGene Expression Regulation NeoplasticVascular endothelial growth factorVascular endothelial growth factor AChemistrySignal TransductionQH301-705.5Recombinant Fusion ProteinsAntibodies Monoclonal HumanizedCatalysisCapillary PermeabilityInorganic ChemistryImmune systemmedicineHumansImmunologic FactorscancerPhysical and Theoretical ChemistryMolecular BiologyQD1-999Vascular Endothelial Growth Factor Receptor-1business.industryOrganic ChemistryEndothelial CellsCancermedicine.diseaseImmunity InnateReceptors Vascular Endothelial Growth FactorchemistryCancer researchbusinessInternational Journal of Molecular Sciences
researchProduct

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

Vascular Endothelial Growth Factor ACancer ResearchLung NeoplasmsAmbrisentanOncology and CarcinogenesisDrug ResistanceBiological AvailabilityAntineoplastic AgentsDrug resistanceCell LineMiceErlotinib HydrochlorideGefitinibIn vivomedicineAnimalsHumansOncology & CarcinogenesisNon-Small-Cell LungProtein Kinase InhibitorsLungCancerTumor microenvironmentTumorEndothelin-1business.industryCarcinomaLung CancerCancerEvaluation of treatments and therapeutic interventionsGefitinibmedicine.diseaseEndothelin 1Xenograft Model Antitumor AssaysErbB ReceptorsOncologyVasoconstriction5.1 Pharmaceuticals6.1 PharmaceuticalsCancer cellMutationCancer researchNeoplasmDevelopment of treatments and therapeutic interventionsbusinessmedicine.drug
researchProduct

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorecta…

2014

Abstract Author Summary Background. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are believed to mediate angiogenesis in colorectal cancer (CRC). Ramucirumab (RAM; IMC-1121B) is a human IgG1 monoclonal antibody that inhibits VEGF ligand binding to VEGFR-2, inhibiting VEGFR-2 activation and signaling. Methods. Patients with metastatic CRC, Eastern Cooperative Oncology Group performance status 0–1, and adequate organ function who had not received chemotherapy for metastatic disease received RAM and the modified FOLFOX-6 regimen every 2 weeks. Endpoints included progression-free survival (PFS), objective response rate, overall survival, and safety. The sample size wa…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyOrganoplatinum CompoundsAngiogenesisColorectal cancerLeucovorinAntibodies Monoclonal HumanizedDisease-Free SurvivalDrug Administration ScheduleRamucirumabchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm Metastasisbusiness.industryClinical Trial ResultsAntibodies MonoclonalKinase insert domain receptormedicine.diseaseVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factorVascular endothelial growth factor ATreatment OutcomeOncologychemistryFluorouracilMonoclonalCancer researchFluorouracilbusinessColorectal Neoplasmsmedicine.drugProtein Binding
researchProduct

Synthesis of Combretastatin A-4 and 3′-Aminocombretastatin A-4 derivatives with Aminoacid Containing Pendants and Study of their Interaction with Tub…

2020

Natural product combretastatin A-4 (CA-4) and its nitrogenated analogue 3&prime

Vascular Endothelial Growth Factor ACell cycle checkpoint<i>htert</i>Pharmaceutical ScienceApoptosisAnalytical Chemistrychemistry.chemical_compound0302 clinical medicineDrug DiscoveryStilbenesc-<i>myc</i>Telomerase0303 health sciences<i>vegf</i>biologyNeovascularization PathologicChemistry3′-aminocombretastatin a-4Cell cycle<i>c-Myc</i>VEGFc-MycBiochemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMCF-7 CellsMolecular Medicinecytotoxicitycell cyclehTERTHT29 CellsArticleProto-Oncogene Proteins c-mycmicrotubuleslcsh:QD241-44103 medical and health sciencesStructure-Activity Relationshiplcsh:Organic chemistryMicrotubuleCell Line TumorHumansPhysical and Theoretical Chemistry030304 developmental biologyCell ProliferationCombretastatinCombretastatin A-4Cell growthOrganic ChemistryAntineoplastic Agents PhytogenicTubulintubulinCell cultureA549 Cellsbiology.proteinM Phase Cell Cycle Checkpointscombretastatin a-4Drug Screening Assays AntitumorMolecules
researchProduct

Arthrinins A–D: Novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.

2011

Bioassay-guided fractionation of a methanolic extract of the fungus Arthrinium sp., isolated from the Mediterranean sponge Geodia cydonium, afforded 10 natural products including five new diterpenoids, arthrinins A-D (1-4) and myrocin D (5). In addition, five known compounds were obtained, which included myrocin A (6), norlichexanthone (7), anomalin A (8), decarboxycitrinone (9) and 2,5-dimethyl-7-hydroxychromone (10). The structures of all isolated compounds were unambiguously elucidated based on extensive 1D and 2D NMR and HR-MS analyzes. The absolute configuration of arthrinins A-D (1-4) was established by the convenient Mosher method performed in NMR tubes and by interpretation of the R…

Vascular Endothelial Growth Factor AClinical BiochemistryPharmaceutical ScienceAntineoplastic AgentsBiochemistryMiceAscomycotaCell Line TumorNeoplasmsDrug DiscoveryAnimalsHumansMTT assayCytotoxicityProtein Kinase InhibitorsMolecular BiologyNeovascularization PathologicKinaseChemistryOrganic ChemistryTerpenoidIn vitroPoriferaEndothelial stem cellVascular endothelial growth factor ABiochemistryCell cultureMolecular MedicineDiterpenesProtein KinasesBioorganic &amp; Medicinal Chemistry
researchProduct